Literature DB >> 30633409

Preoperative neutrophil lymphocyte ratio but not platelet lymphocyte ratio predicts survival and early relapse in patients with oral, pharyngeal, and lip cancer.

Wenjie Yu1,2, Yu Dou3, Ketao Wang3, Yanguo Liu1,4, Jintang Sun1, Han Gao3, Shaohua Liu3, Fengcai Wei3, Daoying Yuan3, Xiaobin Song3, Xun Qu1,5.   

Abstract

BACKGROUND: To evaluate the prognostic value of preoperative neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) in oral, pharyngeal, and lip cancer for survival and relapse.
METHODS: Clinic-pathologic and hematological records were retrospectively retrieved. Patients completed follow-up period were included for survival and relapse analysis.
RESULTS: The preoperative NLR value was a prognostic factor for both overall survival and relapse-free survival. The high NLR group demonstrated higher total relapse rate, higher local relapse rate, and higher relapse rate within 12 months. However, the preoperative PLR did not associate with survival or relapse.
CONCLUSIONS: The preoperative NLR, not PLR, is an independent prognostic indicator of survival. It also exhibits predictive value for relapse, particularly early relapse within 12 months. The preoperative NLR value might be recommended as a useful tool for predicting the outcomes and stratifying patients for different management strategies.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  neutrophil lymphocyte ratio; oral, pharyngeal and lip cancer; overall survival; platelet lymphocyte ratio; relapse rate

Year:  2019        PMID: 30633409     DOI: 10.1002/hed.25580

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  Inflammatory Marker Predicts Outcome of Oral Squamous Cell Carcinoma Receiving Chemo-Radiotherapy.

Authors:  Wei Sun; Meng Gao; Guangyuan Hu; Xun Yuan
Journal:  Cancer Manag Res       Date:  2020-12-01       Impact factor: 3.989

2.  Neutrophil-lymphocyte ratio associated with poor prognosis in oral cancer: a retrospective study.

Authors:  Takumi Hasegawa; Tomoya Iga; Daisuke Takeda; Rika Amano; Izumi Saito; Yasumasa Kakei; Junya Kusumoto; Akira Kimoto; Akiko Sakakibara; Masaya Akashi
Journal:  BMC Cancer       Date:  2020-06-17       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.